Among these, 6 products utilize anti-CD19 CAR-T cells, targeting relapsed or refractory (R/R) B-cell lymphoma and B-cell acute lymphoblastic leukemia (B-ALL), whereas the remaining three products employ anti–B-cell maturation antigen (BCMA) CAR-T cells to treat R/R multiple myeloma (MM) (Table 1). This evidence concerns the gene TNFRSF17 and B-cell acute lymphoblastic leukemia.